Abstract
The HPV Serology Laboratory is leading a global partnership initiative aiming for standardization and harmonization of current serology assay platforms being used to assess immune responses to HPV vaccines. Serology standardization is particularly important given the increasing number of immunobridging trials relying on serology data for approval of new vaccine dosing schedules or vaccine formulations. The initiative was established in 2017 to enable comparisons of data between different vaccines and relevant studies as well as expedite the implementation of new vaccines and vaccine indications. The HPV Serology Laboratory has held or attended several meetings with partnering laboratories, including international meetings in 2017, 2018, and 2021.
Funder
National Cancer Institute
Bill and Melinda Gates Foundation
Publisher
Public Library of Science (PLoS)
Subject
Virology,Genetics,Molecular Biology,Immunology,Microbiology,Parasitology
Reference9 articles.
1. Spotlight on the 9-valent HPV vaccine;PL Lopalco;Drug Des Devel Ther,2017
2. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil(R)) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.;PL McCormack;BioDrugs.,2011
3. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)).;K McKeage;BioDrugs.,2011
4. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.;E Petrosky;MMWR Morb Mortal Wkly Rep,2015
5. Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis;DC Beachler;J Infect Dis,2016